Latest Spinogenix News & Updates

See the latest news and media coverage for Spinogenix. We track all announcements, press releases, and industry mentions in real time, all in one place.

Spinogenix

Biotechnology company developing synapse-restoring therapeutics for brain disorders

spinogenix.com

Headquarters: Los Angeles, United States
Founded year: 2016
Company type: Private company
Number of employees: 4–10
Industry: Pharmaceuticals

Last updated May 5

Latest news about Spinogenix

In short: Spinogenix advanced its pipeline with positive trial data and milestones across Alzheimer's, ALS, schizophrenia, and Fragile X.

Company announcements

May 5 Spinogenix

Spinogenix receives FDA Fast Track Designation for tazbentetol in ALS

This enables expedited development following Phase 2a results showing slowed decline in patients. The company continues its Expanded Access Program.

April 9 Spinogenix

Spinogenix publishes Phase 2a SPG601 results in Nature Scientific Reports

The study shows simultaneous EEG and cognitive improvements in FXS patients. SPG601 has FDA Fast Track and plans for Phase 2b/3 trial.

December 9, 2025 Spinogenix

Spinogenix announces positive Phase IIa results for Alzheimer’s drug

The drug demonstrates disease-modifying potential in the study.

December 8, 2025 Spinogenix

Spinogenix reports cognitive improvements in Alzheimer’s Phase 2a trial

Tazbentetol showed rapid SMMSE gains, sustained benefits in CDR-SB and ADL, favorable safety, and EEG evidence of brain activity improvement.

Media coverage

April 23 Yahoo Finance

Spinogenix Announces CLARITY: a Phase 2b/3 trial of SPG601 for the Treatment of Fragile X Syndrome

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, is initiating CLARITY, a Phase 2b/3...

December 8, 2025 Clinical Trials Arena

Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study

Spinogenix’s once-daily oral therapy has shown potential to offer disease-modifying benefits during a Phase IIa study in Alzheimer’s disease. Image credit: Nefedova Tanya via Shutterstock.com.

December 2, 2025 MarketWatch

Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer's Patients from Phase 2a Trial of TAZBENTETOL (formerly SPG302)

The MarketWatch News Department was not involved in the creation of this content. Tazbentetol, a Potential First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Showed a Favorable...

November 2, 2025 Yahoo

Spinogenix’s ALS hopeful to advance to registrational trial

Spinogenix is progressing its lead candidate, SPG302, to a registrational trial following the...

Never miss news about Spinogenix

Track Spinogenix and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Spinogenix competitors & trending companies

Browse news for competitors to Spinogenix and other trending companies.